New hope for Tough-to-Treat cancers: experimental drug aims to boost chemo power

NCT ID NCT02535312

Summary

This study is testing a new oral drug called TRC102 (methoxyamine) to see if it can make standard chemotherapy drugs more effective against advanced solid tumors and mesothelioma. It aims to find the safest dose and see if the combination can shrink tumors in patients whose cancer has progressed or returned after prior treatment. The trial is for adults with advanced cancers that have spread and are no longer responding to standard therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    Duarte, California, 91010, United States

  • Keck Medical Center of USC Pasadena

    Pasadena, California, 91105, United States

  • Los Angeles General Medical Center

    Los Angeles, California, 90033, United States

  • Mayo Clinic in Rochester

    Rochester, Minnesota, 55905, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • UCHealth University of Colorado Hospital

    Aurora, Colorado, 80045, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland, 21201, United States

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Pittsburgh Cancer Institute (UPCI)

    Pittsburgh, Pennsylvania, 15232, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, 53792, United States

  • Vanderbilt Breast Center at One Hundred Oaks

    Nashville, Tennessee, 37204, United States

  • Vanderbilt University/Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

Conditions

Explore the condition pages connected to this study.